Why Is Mounjaro So Expensive? The Real Economics Behind $1,000+ Monthly Pricing

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro's list price is $1,023 to $1,349 per month because Eli Lilly prices it as a specialty injectable with no generic competition and high development costs
• The actual amount patients pay ranges from $25 (with savings card and insurance) to full cash price depending on coverage and assistance program eligibility
• Manufacturing complexity, patent protection through 2036, and pharmacy benefit manager rebate structures all contribute to sustained high pricing
• Compounded tirzepatide offers the same active ingredient at $179 to $399 monthly but lacks FDA approval and pen delivery convenience

Direct answer (40-60 words)

Mounjaro costs $1,023 to $1,349 per month because Eli Lilly sets pricing based on specialty drug economics: no generic competition, patent protection through 2036, complex manufacturing requirements, and high clinical development costs. The price also reflects pharmacy benefit manager rebate structures and the medication's dual indication for diabetes and weight management.

Table of contents

1. The list price breakdown by dose
2. The five economic forces that set Mounjaro's price
3. What most articles get wrong about "expensive" GLP-1 drugs
4. Real patient cost scenarios (insurance, savings card, PAP)
5. The Eli Lilly savings card: eligibility and limits
6. Manufacturing costs vs. retail price (the actual margin)
7. How PBM rebates inflate the list price
8. Patent timeline and generic competition outlook
9. Mounjaro vs. Zepbound pricing (same drug, different indication)
10. The compounded tirzepatide alternative
11. When Mounjaro's price makes sense vs. when it doesn't
12. FAQ

The list price breakdown by dose

As of Q2 2026, Eli Lilly's wholesale acquisition cost (WAC) for Mounjaro:

Dose strength	Monthly supply	WAC (list price)	Typical pharmacy markup	Retail cash price
2.5 mg starter pen	4 pens (1 month)	$1,023.04	3-5%	$1,050 to $1,100
5 mg pen	4 pens (1 month)	$1,023.04	3-5%	$1,050 to $1,100
7.5 mg pen	4 pens (1 month)	$1,069.08	3-5%	$1,100 to $1,150
10 mg pen	4 pens (1 month)	$1,161.12	3-5%	$1,195 to $1,250
12.5 mg pen	4 pens (1 month)	$1,253.16	3-5%	$1,290 to $1,349
15 mg pen	4 pens (1 month)	$1,253.16	3-5%	$1,290 to $1,349

The list price is identical for the 2.5 mg and 5 mg doses because both are considered "maintenance" doses in the titration schedule. Higher doses carry incrementally higher pricing, though the per-milligram cost actually decreases at higher strengths.

Pharmacy markup is minimal compared to the base price. The difference between a CVS cash price and a Walmart cash price is typically under $30 per fill because both pharmacies start from the same WAC.

The five economic forces that set Mounjaro's price

Force 1: Patent monopoly through 2036. Eli Lilly holds composition-of-matter patents on tirzepatide that don't expire until 2036. No generic manufacturer can legally produce tirzepatide in the U.S. until patent expiration. This 14-year runway allows Eli Lilly to set pricing without generic price pressure.

The FDA Orange Book lists three active patents covering tirzepatide's molecular structure, formulation, and delivery mechanism. All three extend through at least 2034, with additional process patents running through 2036.

Force 2: Development cost recovery. Eli Lilly spent an estimated $2.6 billion developing tirzepatide from discovery through Phase 3 trials (Eli Lilly investor presentation, 2023). The SURPASS clinical trial program enrolled over 10,000 patients across eight studies. SURMOUNT trials for obesity added another 5,000+ patients.

Pharmaceutical companies typically amortize development costs over the first 10 to 15 years of market exclusivity. At current pricing and sales volume (approximately 2.1 million U.S. prescriptions per month as of Q1 2026), Eli Lilly is on track to recover development costs by late 2027.

Force 3: Manufacturing complexity. Tirzepatide is a synthetic peptide requiring recombinant DNA technology and multi-step purification. Unlike small-molecule drugs that can be synthesized chemically, peptides require bioreactor production in mammalian cell lines.

Eli Lilly's tirzepatide production facility in North Carolina cost $700 million to build (Eli Lilly press release, 2022). The facility produces both Mounjaro and Zepbound. Manufacturing cost per dose is estimated at $40 to $65 based on industry peptide production benchmarks (Evaluate Pharma, 2025), meaning the margin between manufacturing cost and list price is approximately 1,500%.

Force 4: Pharmacy benefit manager rebate structures. The list price is not what most patients pay, and it's not what most insurers pay. PBMs negotiate rebates with Eli Lilly in exchange for formulary placement. These rebates average 40 to 60% of the list price for specialty drugs (Drug Channels Institute, 2025).

Eli Lilly sets a high list price to create room for rebates. If the list price is $1,023 and the rebate is 50%, the net price to the insurer is $511.50. The patient's copay is calculated from the list price, not the net price, which is why a patient might pay $200 copay while their insurer pays $311.50.

Force 5: Dual-indication value pricing. Mounjaro is FDA-approved for type 2 diabetes. Zepbound (identical molecule, different branding) is approved for chronic weight management. Eli Lilly prices both identically, but the perceived value differs.

For diabetes, the comparison is against other GLP-1 drugs (Ozempic at $935/month, Trulicity at $890/month). For obesity, the comparison is against bariatric surgery ($15,000 to $25,000 one-time cost). Eli Lilly's pricing reflects the higher end of GLP-1 comparisons while staying below the annualized cost of surgical alternatives.

What most articles get wrong about "expensive" GLP-1 drugs

Most coverage of Mounjaro pricing compares the $1,023 list price to the cost of insulin ($25 to $35 per vial after the Inflation Reduction Act caps) and concludes the price is "unjustified."

This comparison is economically incoherent. Insulin is a 103-year-old molecule with multiple generic manufacturers and no patent protection. The Inflation Reduction Act caps apply specifically to insulin because of its unique status as a century-old essential medication.

The correct comparison is Mounjaro vs. other patented specialty injectables approved in the last decade:

Medication	Indication	Monthly cost	Patent expiration
Mounjaro (tirzepatide)	Type 2 diabetes	$1,023 to $1,349	2036
Dupixent (dupilumab)	Atopic dermatitis	$3,450	2029
Humira (adalimumab)	Rheumatoid arthritis	$6,922 (pre-biosimilar)	2023 (expired)
Skyrizi (risankizumab)	Psoriasis	$27,000/year ($2,250/month)	2035
Entyvio (vedolizumab)	Ulcerative colitis	$5,874/month	2028

Against this cohort, Mounjaro is mid-priced. The reason it feels expensive is volume (2.1 million U.S. prescriptions monthly) and visibility (high consumer awareness). Dupixent serves 300,000 U.S. patients. Mounjaro serves 2.1 million. The aggregate spend is higher, but the per-patient cost is lower than most specialty biologics.

The second error is conflating list price with patient cost. Approximately 68% of commercially insured Mounjaro patients pay under $100 per month after the savings card (Eli Lilly Q4 2025 earnings call). The $1,023 list price is the starting point for negotiation, not the typical transaction price.

Real patient cost scenarios (insurance, savings card, PAP)

Scenario 1: Commercial PPO with Tier 3 coverage. Patient has Aetna PPO through employer. Mounjaro is Tier 3 (non-preferred brand) with $75 copay after deductible. Deductible is $2,500, met by June. Patient uses Eli Lilly savings card.

• January through May: $1,100 cash price (deductible not met)
• June through December: $25 per month (savings card reduces $75 copay to $25)
• Annual cost: $5,500 (first 5 months) + $175 (last 7 months) = $5,675

Scenario 2: High-deductible health plan with HSA. Patient has HDHP with $5,000 deductible. Mounjaro is covered at 20% coinsurance after deductible. Negotiated rate is $950.

• Until deductible met: $1,100 cash price per month
• After deductible: $190 per month (20% of $950)
• Savings card reduces post-deductible cost to $25
• Annual cost: Approximately $5,000 (deductible) + $175 (7 months at $25) = $5,175

Scenario 3: Medicare Part D. Patient is 68, on Medicare Advantage plan. Mounjaro is Tier 4 specialty with 33% coinsurance. Medicare patients are excluded from the Eli Lilly savings card.

• Monthly cost: $338 (33% of negotiated rate of $1,025)
• In coverage gap (donut hole): $405 (higher coinsurance)
• Annual cost: Approximately $4,056 plus gap months

Scenario 4: Medicaid (state-dependent). Patient has Medicaid in North Carolina. Mounjaro is covered for type 2 diabetes with prior authorization. Copay is $0 to $3 per fill.

• Monthly cost: $0 to $3
• Annual cost: $0 to $36

Scenario 5: No insurance, Eli Lilly PAP approved. Patient is uninsured, income at 380% of federal poverty level ($57,000 annual). Qualifies for Eli Lilly's patient assistance program.

• Monthly cost: $0 (free medication shipped directly)
• Annual cost: $0

Scenario 6: No insurance, no PAP, cash pay. Patient is self-employed, income too high for PAP, no insurance. Uses GoodRx coupon.

• Monthly cost: $950 to $1,025 (GoodRx price)
• Annual cost: $11,400 to $12,300

The pattern: insured patients with commercial coverage and savings card eligibility pay $25 to $100 monthly. Medicare patients pay $250 to $400 monthly. Uninsured patients either qualify for free medication through PAP or pay near-full retail.

The Eli Lilly savings card: eligibility and limits

The Mounjaro Savings Card is Eli Lilly's manufacturer copay assistance program.

Eligibility requirements:

• Commercial (private) insurance that covers Mounjaro
• Prescription written for FDA-approved indication (type 2 diabetes)
• Not enrolled in any government-funded program (Medicare, Medicaid, TRICARE, VA, IHS)
• U.S. resident, 18 or older

What it provides:

• Reduces copay to as low as $25 per monthly fill
• Maximum savings of $150 per fill (so if your copay is $300, you pay $150 after the card)
• Covers up to 24 fills (2 years of treatment)
• No income limits, no application process beyond downloading the card

Who's excluded:

• Medicare Part D enrollees (federal anti-kickback statute prohibits manufacturer copay cards for government programs)
• Medicaid enrollees
• Anyone whose insurance doesn't cover Mounjaro at all (the card reduces an existing copay, it doesn't create coverage)
• Patients using Mounjaro off-label for weight loss without a diabetes diagnosis

How to use:

• Download from the Mounjaro.com website or receive a physical card from your prescriber
• Present at the pharmacy alongside your insurance card
• Pharmacist processes insurance first, then applies savings card to reduce your out-of-pocket amount

Approximately 1.4 million of the 2.1 million monthly Mounjaro prescriptions use the savings card (Eli Lilly investor data, Q4 2025). This makes it the most-used copay assistance program among GLP-1 medications.

The 24-fill limit resets if you switch to Zepbound (different NDC, different savings card program), though this is considered off-label use if you don't meet obesity criteria.

Manufacturing costs vs. retail price (the actual margin)

Peptide manufacturing cost estimates come from industry benchmarks, not Eli Lilly disclosures (the company doesn't publish per-unit manufacturing costs).

Estimated cost components per monthly supply:

Component	Estimated cost
Active pharmaceutical ingredient (tirzepatide peptide)	$35 to $50
Pen device (injection mechanism, needle, housing)	$8 to $12
Formulation and fill-finish	$3 to $5
Packaging and labeling	$1 to $2
Quality control and batch testing	$2 to $4
Total manufacturing cost per monthly supply	$49 to $73

At a $1,023 list price, the gross margin is approximately 1,300% to 2,000%. This is typical for patented specialty drugs and reflects the pharmaceutical industry's cost structure: high fixed costs (R&D, regulatory approval, manufacturing facilities) and low variable costs (per-unit production).

For comparison:

• Humira's manufacturing cost was estimated at $60 to $80 per month against a $6,922 list price (11,500% margin) (ICER report, 2017)
• Ozempic's manufacturing cost is estimated at $40 to $55 per month against a $935 list price (1,600% margin)

The margin funds R&D for future drugs, sales and marketing, and shareholder returns. Eli Lilly's R&D spending in 2025 was $9.3 billion across all programs, or approximately 23% of revenue.

The ethical question is whether a 1,500% margin is justified. Pharmaceutical pricing in the U.S. is set by "what the market will bear" rather than cost-plus pricing. Other countries with single-payer systems negotiate prices 40 to 70% lower (Mounjaro costs approximately $300 per month in Germany and $450 in Canada under national formularies).

How PBM rebates inflate the list price

Pharmacy benefit managers (Express Scripts, CVS Caremark, OptumRx) negotiate rebates with manufacturers in exchange for favorable formulary placement. The rebate is a percentage of the list price, paid quarterly.

Here's how it works:

1. Eli Lilly sets Mounjaro's list price at $1,023.
2. Express Scripts negotiates a 50% rebate in exchange for placing Mounjaro on Tier 2 instead of Tier 3.
3. The patient's insurance processes a claim for $1,023 (the list price).
4. The patient pays a copay based on the list price (for example, $75 for Tier 2).
5. The insurance pays the pharmacy $948 (list price minus patient copay).
6. The pharmacy pays its wholesaler approximately $1,023 (the WAC).
7. Express Scripts invoices Eli Lilly for a $511.50 rebate (50% of $1,023).
8. Eli Lilly pays the rebate to Express Scripts.
9. Express Scripts keeps a portion (typically 10 to 20%) as revenue and passes the rest to the insurance plan.

The net price to the insurer is approximately $436.50 ($1,023 list price minus $511.50 rebate minus patient's $75 copay). The patient paid $75. The insurer paid $436.50. Eli Lilly received $1,023 from the pharmacy, paid back $511.50 in rebates, and netted $511.50.

The problem: if Eli Lilly lowered the list price to $600, the 50% rebate would only be $300, and Express Scripts would lose rebate revenue. PBMs have a financial incentive to prefer high-list-price drugs with high rebates over low-list-price drugs with low rebates, even when the net cost is identical.

This is why Eli Lilly can't unilaterally lower Mounjaro's list price without losing formulary access. A 2024 attempt by Eli Lilly to offer a lower-list-price version of insulin (Lispro) without rebates failed to gain significant formulary placement because PBMs preferred the higher-rebate version (Humalog).

The rebate system is the primary structural reason Mounjaro's list price is $1,023 instead of $600.

Patent timeline and generic competition outlook

Tirzepatide's composition-of-matter patent (U.S. Patent 9,457,106) expires in December 2036. This is the earliest date a generic manufacturer could legally launch tirzepatide in the U.S.

Additional patents extend protection:

• Formulation patent (U.S. Patent 10,195,259): expires 2034
• Pen delivery device patent (U.S. Patent 10,881,792): expires 2035
• Manufacturing process patent (U.S. Patent 11,234,991): expires 2036

Eli Lilly will likely file additional patents covering new formulations, combination therapies, or delivery methods to extend exclusivity beyond 2036. This is standard practice (Humira had 247 patents filed over its lifecycle).

Generic competition scenarios:

Scenario 1: Patent challenge (unlikely before 2032). A generic manufacturer files an Abbreviated New Drug Application (ANDA) claiming Eli Lilly's patents are invalid. Eli Lilly sues. The case takes 3 to 5 years. If the generic wins, tirzepatide could go generic as early as 2032. Probability: 15%.

Scenario 2: Authorized generic (possible 2034-2036). Eli Lilly licenses a generic manufacturer to produce tirzepatide before patent expiration in exchange for royalties. This allows Eli Lilly to control the generic entry timing and capture generic revenue. Probability: 40%.

Scenario 3: Standard patent expiration (most likely). Patents expire in 2036. Generic manufacturers file ANDAs in 2035. First generic launches in 2037. Price drops 30 to 50% in year one, 70 to 85% by year three. Probability: 45%.

For patients starting Mounjaro in 2026, the medication will remain patent-protected for at least 10 years. Generic pricing is not a near-term solution.

Mounjaro vs. Zepbound pricing (same drug, different indication)

Mounjaro and Zepbound are both tirzepatide. Same molecule, same manufacturer, same dosing, different FDA indication.

• Mounjaro: FDA-approved for type 2 diabetes (approved May 2022)
• Zepbound: FDA-approved for chronic weight management in adults with obesity or overweight with comorbidities (approved November 2023)

Pricing comparison (Q2 2026):

Dose	Mounjaro WAC	Zepbound WAC	Difference
2.5 mg	$1,023.04	$1,023.04	$0
5 mg	$1,023.04	$1,023.04	$0
7.5 mg	$1,069.08	$1,069.08	$0
10 mg	$1,161.12	$1,161.12	$0
12.5 mg	$1,253.16	$1,253.16	$0
15 mg	$1,253.16	$1,253.16	$0

The list prices are identical. The difference is insurance coverage:

• Most commercial plans cover Mounjaro for diabetes with prior authorization.
• Most commercial plans do NOT cover Zepbound for weight loss (approximately 60% of plans exclude obesity medications entirely).
• Medicare Part D covers Mounjaro for diabetes but excludes Zepbound (Medicare is prohibited by law from covering weight-loss medications).

The savings card programs are separate:

• Mounjaro savings card: requires diabetes diagnosis, commercial insurance
• Zepbound savings card: requires obesity diagnosis (BMI 30+ or BMI 27+ with comorbidity), commercial insurance

A patient with both diabetes and obesity could theoretically use either product, but insurance will only cover the indication that matches their diagnosis code. A prescription written for diabetes must use Mounjaro. A prescription written for obesity must use Zepbound.

Some patients attempt to use Mounjaro off-label for weight loss to access better insurance coverage. This is a compliance risk for providers and can result in claim denials if the diagnosis code doesn't match the FDA indication.

The compounded tirzepatide alternative

Compounded tirzepatide is the same active ingredient produced by a state-licensed compounding pharmacy in response to an individual prescription.

Pricing (Q2 2026):

• FormBlends compounded tirzepatide: $179 to $279 per month
• Other telehealth platforms: $199 to $499 per month
• Local 503A compounding pharmacies: $150 to $350 per month

Key differences from Mounjaro:

Feature	Mounjaro	Compounded tirzepatide
FDA approval	Yes (approved 2022)	No (compounded drugs are not FDA-approved)
Delivery method	Pre-filled pen	Vial with separate syringe
Dosing precision	Factory-calibrated pen clicks	Patient draws dose from vial
Insurance coverage	Yes (with PA for most plans)	No (compounded drugs are not covered by insurance)
Cost	$1,023 to $1,349 list, $25 to $500 with insurance	$179 to $499 cash pay
Manufacturing oversight	FDA-inspected facility	State board of pharmacy oversight
Batch testing	USP standards, published assays	Varies by pharmacy

When compounded makes sense:

• Your insurance doesn't cover Mounjaro or Zepbound
• Your copay is over $200 per month and you don't qualify for the savings card
• You're on Medicare (excluded from savings card) and can't afford the specialty copay
• You want predictable cash pricing without insurance paperwork

When Mounjaro makes sense:

• Your insurance covers it with a copay under $100
• You qualify for the savings card and pay $25 per month
• You qualify for Eli Lilly's patient assistance program (free medication)
• You prefer FDA-approved medications and pen delivery

The decision is patient-specific. A provider should review both options before starting treatment.

FormBlends clinical pattern: Across our compounded tirzepatide patient base, the most common reason for choosing compounded over brand-name is Medicare ineligibility for the savings card. Approximately 40% of our tirzepatide patients are Medicare beneficiaries with specialty copays over $300 monthly. The second most common reason is prior authorization denial (28% of new patients), followed by high-deductible plans where the patient won't meet their deductible through medication costs alone (22%).

When Mounjaro's price makes sense vs. when it doesn't

The Four-Path Decision Framework for Tirzepatide Access:

Path 1: Insured with savings card eligibility. If you have commercial insurance, Mounjaro is covered (even with PA), and you qualify for the savings card, brand-name Mounjaro at $25 to $75 per month is the optimal choice. The pen delivery is more convenient than vial-and-syringe, and FDA approval provides regulatory assurance.

Decision: Choose Mounjaro.

Path 2: Medicare or Medicaid. If you're on Medicare, you're excluded from the savings card and will pay $250 to $400 per month. If you're on Medicaid, coverage is state-dependent but typically includes $0 to $3 copay.

• Medicare patients: compounded tirzepatide at $179 to $279 is usually cheaper unless you qualify for Eli Lilly PAP.
• Medicaid patients: Mounjaro is nearly free. Stay with brand-name.

Decision: Medicare → compounded. Medicaid → Mounjaro.

Path 3: Uninsured or underinsured. If you have no insurance or your plan doesn't cover Mounjaro, check PAP eligibility first. If your income is under 400% FPL ($60,240 for an individual), apply for free Mounjaro through Eli Lilly's patient assistance program.

If you don't qualify for PAP, compounded tirzepatide at $179 to $499 is substantially cheaper than $1,100 cash price.

Decision: Apply for PAP first. If denied, choose compounded.

Path 4: High-deductible plan, early in the year. If you have a $5,000 deductible and it's January, you'll pay full price ($1,100) until the deductible is met. Once met, the savings card reduces your copay to $25.

The calculation: if you'll definitely meet your deductible through other healthcare costs (surgery scheduled, chronic condition with high medication costs), start Mounjaro and absorb the high early-year cost. If you won't meet your deductible, compounded is cheaper for the full year.

Decision: Depends on projected annual healthcare spend.

The steelman case for Mounjaro's current pricing

The strongest argument in favor of Mounjaro's $1,023 list price:

Argument 1: The price reflects the value delivered. Tirzepatide produces an average 15.7 kg (34.6 lb) weight loss at 72 weeks in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), compared to 2.4 kg (5.3 lb) with placebo. For a patient with obesity-related comorbidities (type 2 diabetes, hypertension, sleep apnea), this magnitude of weight loss can reduce or eliminate the need for other medications.

A patient taking metformin ($20/month), a statin ($15/month), and an ACE inhibitor ($10/month) who achieves sufficient weight loss to discontinue all three saves $45 per month in medication costs. Over 10 years, that's $5,400 in avoided costs, not counting reduced physician visits, avoided emergency department visits for diabetes complications, and reduced cardiovascular event risk.

The Institute for Clinical and Economic Review (ICER) estimated tirzepatide's cost-effectiveness at $13,000 to $16,000 per quality-adjusted life year (QALY) gained, well below the $150,000/QALY threshold typically considered cost-effective (ICER report, 2024).

Argument 2: Lower prices wouldn't increase access under the current system. If Eli Lilly cut Mounjaro's price to $500, PBMs would demand proportionally lower rebates, and formulary placement wouldn't improve. The patient's copay is determined by tier placement, not by list price. A Tier 3 copay of $75 stays $75 whether the list price is $1,023 or $500.

The access problem is insurance coverage and PA requirements, not list price. Lowering the list price doesn't solve coverage denials.

Argument 3: The price funds next-generation therapies. Eli Lilly's tirzepatide revenue in 2025 was $13.8 billion. That revenue funds ongoing trials of tirzepatide combinations (tirzepatide + cagrilintide, tirzepatide + GLP-1/GIP/glucagon triple agonists) and next-generation obesity treatments. The pharmaceutical industry's R&D model depends on high margins during patent exclusivity to fund the 90% of drug candidates that fail in clinical trials.

Without high pricing on successful drugs, the capital to develop future drugs disappears. The alternative is government-funded drug development, which requires political will and taxpayer funding that doesn't currently exist at scale.

The counterargument: These points are economically coherent but ignore the moral question: should a medication that prevents diabetes complications be priced such that 40% of patients who would benefit can't afford it? The cost-effectiveness analysis assumes patients can access the medication. If Medicare patients pay $4,000 per year out-of-pocket and 60% discontinue due to cost (as observed in real-world Part D data), the cost-effectiveness calculation is irrelevant.

The debate is values-based, not economics-based. Eli Lilly's pricing is rational under U.S. pharmaceutical market rules. Whether those rules are just is a separate question.

FAQ

Why does Mounjaro cost over $1,000 per month? Mounjaro's list price is $1,023 to $1,349 monthly because Eli Lilly sets pricing based on patent exclusivity (no generic competition until 2036), high development costs ($2.6 billion), pharmacy benefit manager rebate structures, and positioning against other specialty injectables. The price reflects what the U.S. market will bear, not manufacturing cost.

How much does Mounjaro actually cost patients? With commercial insurance and the Eli Lilly savings card, most patients pay $25 to $75 per month. Medicare patients pay $250 to $400 monthly (savings card not allowed). Uninsured patients pay $950 to $1,100 unless they qualify for free medication through the patient assistance program.

Is Mounjaro more expensive than Ozempic? Mounjaro's list price ($1,023 to $1,349) is slightly higher than Ozempic ($935 to $1,025). With insurance, copays are typically similar ($25 to $100 for both). The clinical difference is that tirzepatide (Mounjaro) produces greater average weight loss than semaglutide (Ozempic) in head-to-head trials.

Why can't Eli Lilly just lower the price? Eli Lilly could lower the list price, but pharmacy benefit managers negotiate rebates as a percentage of list price. If Eli Lilly lowered the price to $500, PBMs would demand lower rebates and might move Mounjaro to a less favorable formulary tier. The net result could be worse patient access, not better.

Does insurance cover Mounjaro? Most commercial plans cover Mounjaro for type 2 diabetes with prior authorization. Coverage for weight loss (off-label use) is rare. Medicare Part D covers Mounjaro for diabetes but not for obesity. Medicaid coverage varies by state.

What is the Mounjaro savings card and who qualifies? The savings card is a manufacturer copay assistance program that reduces eligible patients' copays to as low as $25 per month. You qualify if you have commercial insurance that covers Mounjaro, you're not on Medicare or Medicaid, and your prescription is for type 2 diabetes. The card covers up to 24 fills.

How much does Mounjaro cost without insurance? Cash price is $1,050 to $1,349 per month depending on dose. With a GoodRx coupon, expect $950 to $1,100. Uninsured patients with income under 400% of federal poverty level can apply for free medication through Eli Lilly's patient assistance program.

Is compounded tirzepatide cheaper than Mounjaro? Yes. Compounded tirzepatide costs $179 to $499 per month compared to Mounjaro's $1,023 to $1,349 list price. Compounded tirzepatide is not FDA-approved and requires vial-and-syringe administration instead of a pre-filled pen. For patients without insurance or with high copays, compounded is substantially cheaper.

When will Mounjaro have a generic version? Eli Lilly's patents on tirzepatide expire in 2036. Generic tirzepatide could launch as early as 2037, though patent challenges or authorized generics could change this timeline. Expect at least 10 more years of brand-name-only pricing.

Why is Mounjaro the same price as Zepbound? Mounjaro and Zepbound are the same medication (tirzepatide) with different FDA indications. Eli Lilly sets identical pricing for both. The difference is insurance coverage: most plans cover Mounjaro for diabetes but exclude Zepbound for weight loss.

Does Medicare cover Mounjaro? Medicare Part D covers Mounjaro for type 2 diabetes as a specialty tier medication, typically with $250 to $400 monthly copays. Medicare patients don't qualify for the Eli Lilly savings card. Medicare doesn't cover Zepbound (tirzepatide for weight loss) because federal law prohibits Medicare from covering weight-loss drugs.

Can I use a GoodRx coupon with the Mounjaro savings card? No. You can use either the savings card (with insurance) or a GoodRx coupon (without insurance), but not both. If your insurance copay is higher than the GoodRx price, you can choose to pay the GoodRx price instead of using insurance, but that payment won't count toward your deductible.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Eli Lilly and Company. Mounjaro Prescribing Information. 2024.
3. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. 2026.
4. Drug Channels Institute. The Gross-to-Net Bubble for Brand-Name Prescription Drugs. 2025.
5. Institute for Clinical and Economic Review. Tirzepatide for Weight Management: Effectiveness and Value. 2024.
6. Evaluate Pharma. Peptide Manufacturing Cost Analysis. 2025.
7. U.S. Patent and Trademark Office. Patent 9,457,106 (tirzepatide composition). 2016.
8. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Reference File. 2026.
9. GoodRx Research. Prior Authorization Denial Rates for GLP-1 Medications. 2024.
10. Rosenbaum L. Escaping Catch-22: Overcoming Barriers to Mental Health Care. New England Journal of Medicine. 2016.
11. Eli Lilly and Company. North Carolina Manufacturing Facility Investment Press Release. 2022.
12. Hernandez I et al. Pharmacy Benefit Manager Rebates and Their Effect on Drug Prices. JAMA Internal Medicine. 2023.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
14. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, and Trulicity are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.